摘要
富马酸吉特替尼(Gilteritinib)是一种新型、强效、高选择性、可口服的FLT3/AXL抑制剂。于 2018 年 11 月 28 日经美国食品药品监督管理局(FDA)批准上市,是第一个也是目前唯一用于FLT3突变的复发性或难治性急性髓性白血病成人患者的靶向药物。本文主要对吉特替尼的药理作用、药代动力学参数、临床适应证、用法用量、药物间相互作用、禁忌与注意事项及临床常见的用药后不良反应进行介绍,以期为临床用药提供帮助与指导。
Gilteritinib fumarate is a novel,potent,highly selective and oral (FLT3) / AXL inhibitor,which was approved by the Food and Drug Administration (FDA) on November 28,2018.It is the first and also the only targeting drug for adult patients with FLT3 mutation in relapsed or refractory acute myeloid leukaemia.In this paper,we mainly introduced its pharmacological action,pharmacokinetic parameters,clinical indications,usage and dosage,drug interactions,taboos and precautions,and common adverse reactions,so as to provide help and guidance for clinical drug use.
作者
赵爽
张莹
王相峰
李月阳
ZHAO Shuang;ZHANG Ying;WANG Xiangfeng;LI Yueyang(Department of Pharmacy,the First Hospital of Jilin University,Changchun,Jilin,130021,China)
出处
《肿瘤药学》
CAS
2019年第6期957-960,共4页
Anti-Tumor Pharmacy
